Another strategy involves the manufacture of genetically engineered T cells that are precisely designed to target a patient’s unique cancer. This process—yet another example of ex vivo therapy—is known as adoptive cell transfer, and it’s in this mode of immunotherapy that gene editing enters the picture.
